Weiss Ratings Reaffirms Sell (D-) Rating for SOPHiA GENETICS (NASDAQ:SOPH)

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report)'s stock had its "sell (d-)" rating restated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

SOPHiA GENETICS Trading Up 7.7%

SOPHiA GENETICS stock opened at $4.48 on Wednesday. The company has a 50 day moving average price of $3.54 and a 200 day moving average price of $3.25. SOPHiA GENETICS has a 52 week low of $2.58 and a 52 week high of $4.92. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.21 and a current ratio of 3.39. The firm has a market capitalization of $302.76 million, a price-to-earnings ratio of -10.18 and a beta of 1.10.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.58. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. The firm had revenue of $18.32 million during the quarter, compared to analyst estimates of $17.49 million. SOPHiA GENETICS has set its FY 2025 guidance at EPS. Research analysts forecast that SOPHiA GENETICS will post -0.96 EPS for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. Bank Pictet & Cie Europe AG boosted its stake in SOPHiA GENETICS by 14.4% in the 1st quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock worth $847,000 after purchasing an additional 32,200 shares during the period. Ridgewood Investments LLC lifted its position in SOPHiA GENETICS by 1,930.5% in the 1st quarter. Ridgewood Investments LLC now owns 40,610 shares of the company's stock worth $135,000 after buying an additional 38,610 shares in the last quarter. Federated Hermes Inc. lifted its position in SOPHiA GENETICS by 89.0% in the 1st quarter. Federated Hermes Inc. now owns 189,000 shares of the company's stock worth $627,000 after buying an additional 89,000 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after buying an additional 5,432,871 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC lifted its position in SOPHiA GENETICS by 31.8% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company's stock worth $142,000 after buying an additional 11,040 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.